Changping Wu

2.1k total citations
41 papers, 1.6k citations indexed

About

Changping Wu is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Changping Wu has authored 41 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 18 papers in Molecular Biology and 10 papers in Immunology. Recurrent topics in Changping Wu's work include Cancer Immunotherapy and Biomarkers (8 papers), MicroRNA in disease regulation (7 papers) and RNA modifications and cancer (7 papers). Changping Wu is often cited by papers focused on Cancer Immunotherapy and Biomarkers (8 papers), MicroRNA in disease regulation (7 papers) and RNA modifications and cancer (7 papers). Changping Wu collaborates with scholars based in China, United States and Taiwan. Changping Wu's co-authors include Jingting Jiang, Yiting Geng, Wenxiu Wang, Hongbing Shi, Bin Xu, Lujun Chen, Liangrong Shi, Mei Ji, Weiqing Zhao and Haifeng Deng and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Hepatology.

In The Last Decade

Changping Wu

41 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Changping Wu China 21 745 596 511 433 208 41 1.6k
Libo Chen China 16 454 0.6× 372 0.6× 196 0.4× 376 0.9× 145 0.7× 52 1.3k
Tiziana Apuzzo Italy 11 686 0.9× 622 1.0× 258 0.5× 442 1.0× 114 0.5× 12 1.5k
Xiao Hai Li China 21 421 0.6× 439 0.7× 130 0.3× 462 1.1× 119 0.6× 46 1.3k
Shung‐Haur Yang Taiwan 18 631 0.8× 730 1.2× 295 0.6× 109 0.3× 170 0.8× 40 1.4k
T Tokunaga Japan 22 942 1.3× 641 1.1× 438 0.9× 218 0.5× 300 1.4× 36 1.6k
Anne Sofie Siebuhr Denmark 23 441 0.6× 256 0.4× 194 0.4× 222 0.5× 123 0.6× 69 2.0k
Susan C. Hubchak United States 19 1.0k 1.4× 218 0.4× 390 0.8× 115 0.3× 170 0.8× 30 1.8k
Jiaxi Song China 25 1.1k 1.5× 852 1.4× 750 1.5× 525 1.2× 597 2.9× 60 2.4k
Jinghong Xu China 20 562 0.8× 325 0.5× 463 0.9× 128 0.3× 162 0.8× 80 1.5k
Sophia K. Khaldoyanidi United States 24 788 1.1× 389 0.7× 151 0.3× 509 1.2× 144 0.7× 50 1.7k

Countries citing papers authored by Changping Wu

Since Specialization
Citations

This map shows the geographic impact of Changping Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changping Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changping Wu more than expected).

Fields of papers citing papers by Changping Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changping Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changping Wu. The network helps show where Changping Wu may publish in the future.

Co-authorship network of co-authors of Changping Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Changping Wu. A scholar is included among the top collaborators of Changping Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changping Wu. Changping Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Geng, Yiting, Xiao Zheng, Dachuan Zhang, et al.. (2024). CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration. Biology Direct. 19(1). 36–36. 14 indexed citations
2.
Cheng, Gui, Jun Wu, Mei Ji, et al.. (2023). TET2 inhibits the proliferation and metastasis of lung adenocarcinoma cells via activation of the cGAS-STING signalling pathway. BMC Cancer. 23(1). 825–825. 19 indexed citations
3.
Chang, Chia‐Hsieh, et al.. (2021). Would foot arch development in children characterize a body maturation process? A prospective longitudinal study. Biomedical Journal. 45(5). 828–837. 6 indexed citations
4.
Xu, Yanjie, Jiemin Zhao, Cao Gao, et al.. (2021). Hsa_circ_0136666 activates Treg-mediated immune escape of colorectal cancer via miR-497/PD-L1 pathway. Cellular Signalling. 86. 110095–110095. 48 indexed citations
5.
6.
Zhang, Luo, Xing Song, Xin Chen, et al.. (2019). Circular RNA CircCACTIN Promotes Gastric Cancer Progression by Sponging MiR-331-3p and Regulating TGFBR1 Expression. International Journal of Biological Sciences. 15(5). 1091–1103. 85 indexed citations
7.
Wang, Wenxiu, Jingting Jiang, & Changping Wu. (2019). CAR-NK for tumor immunotherapy: Clinical transformation and future prospects. Cancer Letters. 472. 175–180. 160 indexed citations
8.
Shi, Liangrong, Junjun Wang, Nianhua Ding, et al.. (2019). Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. Nature Communications. 10(1). 5421–5421. 203 indexed citations
9.
Geng, Yiting, Jingting Jiang, & Changping Wu. (2018). Function and clinical significance of circRNAs in solid tumors. Journal of Hematology & Oncology. 11(1). 98–98. 207 indexed citations
10.
Yan, Haijiao, Qing Li, Jun Wu, et al.. (2017). MiR-629 promotes human pancreatic cancer progression by targeting FOXO3. Cell Death and Disease. 8(10). e3154–e3154. 43 indexed citations
11.
Jun, Wu, et al.. (2016). Evaluate the correlation between preoperative systemic immune-inflammation index and prognosis of patients after curative resection for cardia gastric cancer. 11(6). 510–514. 3 indexed citations
12.
Sun, Yuanjue, Yongqian Shu, Baorui Liu, et al.. (2016). A prospective study to evaluate the efficacy and safety of oral acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy. Experimental and Therapeutic Medicine. 12(6). 4017–4024. 19 indexed citations
13.
Ji, Mei, Yan Liu, Qing Li, et al.. (2016). PD-1/PD-L1 expression in non-small-cell lung cancer and its correlation with EGFR/KRAS mutations. Cancer Biology & Therapy. 17(4). 407–413. 106 indexed citations
14.
Li, Chong, et al.. (2015). SIRT1 expression is associated with poor prognosis of lung adenocarcinoma. OncoTargets and Therapy. 8. 977–977. 36 indexed citations
15.
Gao, Qingqing, Lili Li, Jiaqi Tang, et al.. (2014). Exposure to Nicotine During Pregnancy and Altered Learning and Memory in the Rat Offspring. Nicotine & Tobacco Research. 17(6). 661–666. 20 indexed citations
16.
Ji, Mei, Xiaodong Li, Hanze Zhang, et al.. (2014). Report of clinical studies on chronochemotherapy for advanced non-small cell lung cancer in China. Tumor Biology. 35(12). 12285–12292. 1 indexed citations
17.
Shi, Hongbing, Jun Wu, Mei Ji, et al.. (2013). Serum lemur tyrosine kinase 3 expression in colorectal cancer patients predicts cancer progression and prognosis. Medical Oncology. 30(4). 754–754. 17 indexed citations
18.
Zhang, Yi, Yi Zhang, Wei Cai, et al.. (2013). Mesenchymal Stem Cells Alleviate Bacteria-Induced Liver Injury in Mice by Inducing Regulatory Dendritic Cells. Hepatology. 59(2). 671–682. 106 indexed citations
19.
Li, Zhengguang, Jun Wu, Changping Wu, et al.. (2012). Deguelin, a natural rotenoid, inhibits mouse myeloma cell growth in vitro via induction of apoptosis. Oncology Letters. 4(4). 677–681. 8 indexed citations
20.
Wu, Changping, Ning Xu, Yibei Zhu, et al.. (2009). Clinical evaluation of serum alpha‐fetoprotein–IgM immune complexes on the diagnosis of primary hepatocellular carcinoma. Journal of Clinical Laboratory Analysis. 23(4). 213–218. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Libo Chen Breakdown of academic impact, for papers by Tiziana Apuzzo Breakdown of academic impact, for papers by Xiao Hai Li Breakdown of academic impact, for papers by Shung‐Haur Yang Breakdown of academic impact, for papers by T Tokunaga Breakdown of academic impact, for papers by Anne Sofie Siebuhr Breakdown of academic impact, for papers by Susan C. Hubchak Breakdown of academic impact, for papers by Jiaxi Song Breakdown of academic impact, for papers by Jinghong Xu Breakdown of academic impact, for papers by Sophia K. Khaldoyanidi
Rankless by CCL
2026